
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics is a promising clinical-stage biotechnology company with a diverse portfolio of programs aimed at treating neurological and psychiatric disorders. Its lead program is RAP-219, a small molecule therapy targeting AMPA receptors, which has shown potential for treating focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. With a solid understanding of RAP biology and a unique approach in targeting specific receptor variants, Rapport Therapeutics has the potential to offer differentiated treatments for these conditions and significant upside potential for investors.
Bears say
Rapport Therapeutics is a clinical-stage biotechnology company in the United States. It has a promising portfolio of small-molecule precision medicines for neurological and psychiatric disorders, including RAP-219 for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. However, the company has a high risk profile due to its developmental phase and lack of marketing experience, and its success hinges on regulatory, developmental, and commercial factors. Additionally, there may be competition in the therapeutic indications it hopes to launch its drugs in, and its current negative earnings and cash flows pose financial risks.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares